Found: 236
Select item for more details and to access through your institution.
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 19, p. 3333, doi. 10.1002/cncr.35388
- By:
- Publication type:
- Article
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 9, p. 1790, doi. 10.1002/ajh.27434
- By:
- Publication type:
- Article
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 7, p. 1434, doi. 10.1002/ajh.27333
- By:
- Publication type:
- Article
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 792, doi. 10.1002/ajh.27236
- By:
- Publication type:
- Article
Toward an improved understanding of hypomethylating agent and venetoclax therapies.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 2, p. 152, doi. 10.1002/ajh.27178
- By:
- Publication type:
- Article
Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1711, doi. 10.1002/ajh.27054
- By:
- Publication type:
- Article
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 9, p. E233, doi. 10.1002/ajh.27005
- By:
- Publication type:
- Article
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 9, p. 1383, doi. 10.1002/ajh.26997
- By:
- Publication type:
- Article
DDX41 mutations in patients with non‐myeloid hematologic neoplasms.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 8, p. E193, doi. 10.1002/ajh.26952
- By:
- Publication type:
- Article
The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. 658, doi. 10.1002/ajh.26852
- By:
- Publication type:
- Article
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. 493, doi. 10.1002/ajh.26816
- By:
- Publication type:
- Article
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimens.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. E53, doi. 10.1002/ajh.26811
- By:
- Publication type:
- Article
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1599, doi. 10.1002/ajh.26731
- By:
- Publication type:
- Article
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1560, doi. 10.1002/ajh.26724
- By:
- Publication type:
- Article
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. E422, doi. 10.1002/ajh.26707
- By:
- Publication type:
- Article
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1427, doi. 10.1002/ajh.26700
- By:
- Publication type:
- Article
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD‐negative remission.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. E408, doi. 10.1002/ajh.26698
- By:
- Publication type:
- Article
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐A.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. E416, doi. 10.1002/ajh.26692
- By:
- Publication type:
- Article
A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. 1127, doi. 10.1002/ajh.26630
- By:
- Publication type:
- Article
Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. 1035, doi. 10.1002/ajh.26601
- By:
- Publication type:
- Article
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. E299, doi. 10.1002/ajh.26600
- By:
- Publication type:
- Article
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 885, doi. 10.1002/ajh.26572
- By:
- Publication type:
- Article
Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 856, doi. 10.1002/ajh.26550
- By:
- Publication type:
- Article
Prediction of survival with intensive chemotherapy in acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 865, doi. 10.1002/ajh.26557
- By:
- Publication type:
- Article
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 5, p. 574, doi. 10.1002/ajh.26496
- By:
- Publication type:
- Article
Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. 329, doi. 10.1002/ajh.26451
- By:
- Publication type:
- Article
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 2, p. E62, doi. 10.1002/ajh.26417
- By:
- Publication type:
- Article
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 1, p. 68, doi. 10.1002/ajh.26395
- By:
- Publication type:
- Article
Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 11, p. 1420, doi. 10.1002/ajh.26314
- By:
- Publication type:
- Article
Post‐transplantation donor‐derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 9, p. E350, doi. 10.1002/ajh.26266
- By:
- Publication type:
- Article
Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 914, doi. 10.1002/ajh.26206
- By:
- Publication type:
- Article
FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. E275, doi. 10.1002/ajh.26202
- By:
- Publication type:
- Article
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) and myelodysplastic syndrome with ring sideroblasts (MDS‐RS).
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. E246, doi. 10.1002/ajh.26182
- By:
- Publication type:
- Article
Differentiation syndrome with lower‐intensity treatments for acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 6, p. 735, doi. 10.1002/ajh.26142
- By:
- Publication type:
- Article
Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 5, p. E154, doi. 10.1002/ajh.26122
- By:
- Publication type:
- Article
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low‐intensity induction with venetoclax.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 3, p. E65, doi. 10.1002/ajh.26060
- By:
- Publication type:
- Article
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 2, p. 241, doi. 10.1002/ajh.26047
- By:
- Publication type:
- Article
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 2, p. E50, doi. 10.1002/ajh.26044
- By:
- Publication type:
- Article
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 2, p. 208, doi. 10.1002/ajh.26039
- By:
- Publication type:
- Article
Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 11, p. E313, doi. 10.1002/ajh.25965
- By:
- Publication type:
- Article
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 9, p. E225, doi. 10.1002/ajh.25854
- By:
- Publication type:
- Article
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 6, p. 612, doi. 10.1002/ajh.25769
- By:
- Publication type:
- Article
Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 2, p. 227, doi. 10.1002/ajh.25610
- By:
- Publication type:
- Article
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 9, p. 984, doi. 10.1002/ajh.25553
- By:
- Publication type:
- Article
Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 7, p. E188, doi. 10.1002/ajh.25490
- By:
- Publication type:
- Article
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk disease.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 7, p. 757, doi. 10.1002/ajh.25486
- By:
- Publication type:
- Article
A phase II study of omacetaxine mepesuccinate for patients with higher‐risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 1, p. 74, doi. 10.1002/ajh.25318
- By:
- Publication type:
- Article
Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 3, p. 401, doi. 10.1002/ajh.25000
- By:
- Publication type:
- Article
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 2, p. 277, doi. 10.1002/ajh.24972
- By:
- Publication type:
- Article
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 1, p. 84, doi. 10.1002/ajh.24943
- By:
- Publication type:
- Article